Skip to content


David R. Epstein

Executive Partner

David Epstein is an Executive Partner at Flagship Pioneering. He serves on the board of several Flagship companies including Rubius Therapeutics, Evelo Biosciences, Axcella Therapeutics, Ring Therapeutics, and Valo Health. He is also a board member at Tarus Therapeutics, Woolsey Pharmaceuticals, Dynamics Special Purpose Corp, and Opy Acquisition Corp.

David supports two non-profits as a Director at Three Opinions Foundation and Chairman of South Florida’s Pelican Harbor Seabird Station (PHSS). PHSS is Miami’s premier native wildlife hospital dedicated to the rescue, rehabilitation, and release of sick, injured or orphaned brown pelicans, seabirds, and other native wildlife thus enabling future generations.

From early 2010 to mid-2016, David served as chief executive officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Under his leadership the company’s oncology business grew to the second largest in the world.

David has more than 25 years of extensive drug development, deal making, commercialization and leadership experience on a global scale. Over the course of his career he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Afinitor, Cosentyx and Entresto. His teams developed 3 Prix Galien award winning medicines and he has developed several CEOs. He was named by FierceBiotech as one of the “25 most influential people in biopharma.”

Early in his career, David was an associate in the strategy practice of consulting firm Booz, Allen and Hamilton. David holds a B.S. in pharmacy from Rutgers University College of Pharmacy (1984) and an M.B.A. in finance and marketing from the Columbia University Graduate School of Business (1987).